A Phase I/II Study of Foretinib in Combination with Lapatinib in Patients with Human Epidermal Growth Factor Receptor 2(HER2)Over-Expressing Metastatic Breast Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 16 May 2017
At a glance
- Drugs Foretinib (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 15 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 07 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Sep 2014.
- 21 Sep 2013 Lead centres updated as reported by ClinicalTrials.gov.